Effective Fetal Epigenetic Biomarkers for Noninvasive Fetal Trisomy 21 Detections

Fetal Diagn Ther. 2019;46(2):133-138. doi: 10.1159/000494054. Epub 2018 Nov 8.

Abstract

Introduction: Recently, we identified three novel fetal-specific epigenetic DNA regions (FSERs) on chromosome 21 for detection of noninvasive fetal trisomy 21 (T21). In this study, the diagnostic accuracies of the three FSERs were assessed on a larger panel of the first-trimester pregnant women.

Material and methods: This study was conducted with maternal plasma collected from 167 pregnant women carrying 155 chromosomally normal and 12 T21 fetuses (10-13 gestational weeks). Accuracies of FSERs for noninvasive prenatal test of fetal T21 were estimated by the area under the receiver operator characteristic curve (AUC).

Results: The levels of all FSERs increased in pregnant women with T21 fetuses when compared with controls (p < 0.001 for all). The levels of the three FSERs did not differ according to maternal age, body mass index, and fetal sex at maternal blood sampling (p > 0.05 for all). In noninvasive fetal T21 detection, the AUC of FSER1, FSER2, and FSER3 were 0.859 (95% CI: 0.746-0.972), 0.919 (95% CI: 0.856-0.982), and 0.868 (95% CI: 0.746-0.990), respectively.

Discussion: The findings of this study suggest that all FSERs may be useful for noninvasive fetal T21 detection, regardless of maternal age, body mass index, and fetal sex.

Keywords: Cell-free fetal DNA; DNA methylation; Epigenetics; Noninvasive prenatal test.

MeSH terms

  • Area Under Curve
  • Body Mass Index
  • DNA Methylation
  • Down Syndrome / diagnosis*
  • Epigenesis, Genetic
  • Female
  • Humans
  • Male
  • Maternal Age
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Pregnancy Outcome
  • ROC Curve